Cadonilimab - Akeso Biopharma
Alternative Names: AK-104Latest Information Update: 28 Jun 2024
At a glance
- Originator Akeso Biopharma
- Developer Akeso Biopharma; Chipscreen Biosciences; Hunan Cancer Hospital; Sun Yat-Sen University; The Third Affiliated Hospital of Soochow University
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer
- Preregistration Gastric cancer; Oesophageal cancer
- Phase III Liver cancer; Non-small cell lung cancer
- Phase II Nasopharyngeal cancer; Ovarian cancer; Rectal cancer; Renal cell carcinoma; Solid tumours
- Phase I/II Malignant melanoma; Pancreatic cancer; Peripheral T-cell lymphoma; Small cell lung cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV)
- 19 Jun 2024 Phase-III clinical trials in Gastric cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06341335)
- 31 May 2024 Interim efficacy and adverse events data from a phase II trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)